Besides, dual circumvention of VEGFR2 and Aurora A/B is a promising approach for improving antiproliferative activity versus multiple cancer species; compound 18 showed hampering activity versus VEGFR2, Aurora A, and B with IC50 value of 46.65 nM relative to Sunitinib IC50 value of 42.33 nM, IC50 equal to 16.83 nM higher than Sunitinib IC50 value of 48.42 nM, and IC50 equal to 29.38 nM less than Sunitinib IC50 value of 17.33 nM, respectively. This evidence concerns the gene KDR and cancer.